Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01952 EVEREST MED-B
RTNominal up23.500 +1.600 (+7.306%)
Research Report

06/10/2021 17:28

{I-bank focus}Morgan lowers Everest Med (01952) to HK$96.24

[ET Net News Agency, 6 October 2021] Morgan Stanley lowered its target price for
Everest Med (01952) to HK$96.24 from HK$105 and maintained its "overweight" rating.
The research house said it has expanded losses from 2021-24 by 4-13%, as well as
trimming earnings in 2026-30 by 2-8% considering: (1) recent licensing deals to be
executed by Everest, including COVID-19 mRNA vaccine, BTK asset, and biologics; (2)
expanded costs of roadmap to full-integration, including in-house discovery engine and
commercial team; (3) updated R&D and administrative costs for 2021-22 based on 1H21 and
historical trends; and (4) updated currency changes within its model. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.